Yinjia Bio Secures Tens of Millions of RMB in Angel Funding Led by CDH Investments and Followed by Furong Investment

VCBeat (WeChat: vcbeat) learned at the earliest opportunity,2021Year2Month1Day 0, Shanghai, ChinaA company dedicated to developingA company specializing in upstream core raw materials and cutting-edge companion diagnostic products, YINJIA BIOSCIENCES (Shanghai) Co., Ltd. (hereinafter referred to as“YINJIA BIOSCIENCES” announced the completion of its angel round financing, amounting to tens of millions of RMB. The round was led by CDH Investments, with participation from Furong Investment.YINJIA BIOSCIENCES at2020Established in the Lingang New Area of the Shanghai Pilot Free Trade Zone, with R&D and production bases simultaneously established in Shanghai, Beijing, and Suzhou.

Dr. Wu Yifei, Founder of YINJIA BIOSCIENCES, previously served as Vice President and General Manager of the Clinical Diagnostics and Reagents Division at WuXi AppTec. He earned his Ph.D. in Cell and Molecular Biology from the University of Michigan Medical School and has 18 years of overseas study and work experience. His industrial career abroad included roles as a Senior Development Scientist for core diagnostic protein raw materials and immunoassay reagents at Roche Diagnostics in the United States, and as a Senior Process Development Scientist for protein therapeutics at Cook Pharmica (now part of Cook Medical). Upon returning to China in early 2008, Dr. Wu held leadership positions at companies including Medicilon Beijing, Yangtze River Pharmaceutical Group, and Rendong Medicine. With extensive experience in the development, manufacturing, and project management of protein therapeutics and diagnostic products, coupled with over a decade of collaboration with more than 90 leading domestic and international pharmaceutical companies, biotech firms, and hospitals since his return, Dr. Wu has accumulated substantial hands-on expertise in operations management and regulatory oversight across both the pharmaceutical and diagnostics sectors. Additionally, the core team at YINJIA BIOSCIENCES comprises highly experienced returnee Ph.D.s and Master’s degree holders, along with key technical, marketing, and sales professionals who have many years of frontline practical experience. These team members have previously engaged in the R&D, production, and operational management of novel drugs and diagnostic reagents at renowned pharmaceutical and diagnostics enterprises.

Dr. Wu Yifei, Founder, Chairman, and CEO of YINJIA BIOSCIENCESStatement: We sincerely appreciate the support and trust extended to us by two renowned domestic investment institutions. YINJIA BIOSCIENCES will leverage a suite of modern protein technologies—including computer simulation, AI-assisted design, and our proprietary CFPS (Cell-Free Protein Selective) technology—to build a comprehensive protein development platform. We aim to provide high-quality, difficult-to-replicate, highly stable, and cost-effective protein raw materials and reagents that meet international standards, serving clinical diagnostics, personalized medication guidance, new drug R&D, and other areas with unmet needs. Our goal is to become a high-tech platform company focused on multi-level protein applications, combining source innovation with internationally advanced collaborative development.With the funds from this financing round, YINJIA BIOSCIENCES will attract core talent and initially establish an innovative R&D and production base in China. We will develop core reagents for early diagnosis of malignant tumors, as well as a series of critical protein raw materials that are currently heavily reliant on imports and in high demand within the domestic market. This will lay a solid foundation for the subsequent development and clinical trials of innovative diagnostic products centered on early cancer detection, adjuvant immunotherapy, and cell therapy.

Dr. Liu Dan, Partner at CDH VGC (Innovation and Growth Fund)“It has become key to China’s independent innovation in tumor diagnostics or immunotherapy technologies to develop protein raw materials with proprietary intellectual property rights and performance comparable to global leading standards. Leveraging its proprietary CFPS platform for unique protein selection and other technologies, YINJIA BIOSCIENCES has established deep collaborations with internationally renowned scholars and research institutions. Through independent innovation, joint development, and international licensing arrangements, the company has built a robust protein R&D technology platform to develop and market core critical protein raw materials for the Chinese and even global markets, holding significant future potential. Dr. Wu Yifei is not only a rare managerial scientist in original protein R&D within China, but also one of the earliest advocates of companion diagnostics and precision medicine in the industry. CDH Investments will support YINJIA BIOSCIENCES in sustaining innovation, researching and developing leading high-end, high-quality core critical protein raw materials, addressing unmet needs in China’s tumor diagnostics and immunotherapy sectors, promoting industry advancement, and continuously creating social value.”

Dr. Sun Pengjun, Chairman of Furong InvestmentIt stated: “Reagent raw materials hold significant strategic importance throughout the in vitro diagnostics (IVD) industry chain, as innovations in downstream clinical application technologies often require support at the raw material level. Indeed, the performance limits of certain core reagents largely determine the upper bound of IVD system performance. Currently, China’s core reagent industry relies heavily on imports, with foreign manufacturers holding a monopolistic position that keeps costs prohibitively high, severely undermining the international competitiveness of Chinese enterprises. The inability to fully guarantee the continuous and stable supply of imported core raw materials poses a serious threat to the industrial security of the entire IVD sector. Furong Investment’s participation in the angel financing round of YINJIA BIOSCIENCES aims to leverage Dr. Wu Yifei’s team’s extensive expertise in the companion diagnostics and precision medicine industries to pioneer new frontiers in the original research and development of proteins. We believe that this experienced team will become a leader in protein R&D within the fields of tumor diagnostics or immunotherapy technology, both in China and globally, by continuously driving innovation and attracting top-tier professional talent from around the world.”

YINJIA BIOSCIENCES, established in November 2020, is a technology platform company focused on multi-level protein applications, committed to both source innovation and international collaborative development. By establishing in-depth partnerships with leading international scholars and research institutions, the company has built a protein R&D technology platform through independent innovation, joint development, and international licensing. It develops, manufactures, and sells core key protein raw materials and reagents for the Chinese and global markets. Leveraging this platform, YINJIA BIOSCIENCES also develops key core protein reagents for early tumor diagnosis, personalized medication guidance, adjuvant tumor immunotherapy, and cell therapy, thereby benefiting patients. The company is registered in the Lingang New Area of the Shanghai Free Trade Zone, with its R&D center located in Shanghai, its production base in Suzhou Industrial Park, and an R&D and registration center in Beijing.

CDH Investments, established in 2002, is one of the most influential alternative asset management firms in China. As of 2020, its assets under management exceeded RMB 160 billion. CDH Investments operates six major business segments: private equity, innovation and growth, securities investment, real estate investment, mezzanine investment, and wealth management. CDH VGC (Venture & Growth Capital) focuses on investing in healthcare, TMT, and innovative growth opportunities with Chinese characteristics. The CDH Innovation and Growth Fund is managed by an experienced and distinctive professional investment team dedicated to fostering innovation and development in high-potential growth-stage companies. Leveraging CDH Investments’ outstanding performance in healthcare and growth-sector investments, as well as its strategic focus on the TMT sector, the CDH Innovation and Growth Fund has developed unique investment strategies and platform advantages. By drawing on the investment team’s extensive experience, professional judgment, and operational management expertise, the fund comprehensively enhances the value of its portfolio companies.

Furong Investment is a sci-tech finance and innovation & entrepreneurship platform initiated by the Ningbo Institute of Fudan University. Leveraging Fudan University’s robust advantages in talent, scientific research, academia, and clinical resources, it promotes the industrialization of related scientific and technological achievements and fosters innovation and entrepreneurship among high-level talents. Actively serving national innovation-driven development strategies, including the integrated development of the Yangtze River Delta region and Shanghai’s initiative to build a globally influential science and technology innovation center, Furong Investment focuses on incubating and investing in early-to-mid-stage projects in fields such as life and health, integrated circuits, new energy, and new materials.